Q4 2025 VolitionRX Ltd Earnings Call Transcript
Key Points
- VolitionRX Ltd (VNRX) received its first order for the Nu.Q Cancer assays for clinical certification in lung cancer, marking a significant step towards routine clinical use.
- The company announced the inclusion of its Nu.Q NETs assay in a $7.3 million government-backed program in France for early detection of sepsis.
- VolitionRX Ltd (VNRX) signed two significant agreements with multibillion-dollar companies, Werfen and Hologic, to commercialize its Nu.Q platform in the human diagnostic market.
- The company recorded its first revenue from the CE-marked Nu.Q NETs automated assay, with 12 hospital networks evaluating its use across 15 clinical indications.
- VolitionRX Ltd (VNRX) achieved a 40% revenue growth in 2025 compared to 2024, with a significant reduction in operating expenses by 17%.
- Revenues remain unpredictable and lumpy at this early stage of commercialization, leading to the decision not to provide revenue guidance for 2026.
- Despite progress, the company reported a net cash usage of $19.7 million in operating activities for 2025, highlighting ongoing financial challenges.
- Cash and cash equivalents were low at approximately $1.1 million at the end of 2025, necessitating additional funding through ATM facilities and convertible notes.
- The commercialization of the Nu.Q Vet Cancer Test is dependent on central lab automation, which is still in progress, affecting the speed of revenue growth.
- The company is still in the process of securing reimbursement for its Nu.Q Cancer assays in France, with routine clinical use expected only by the fourth quarter of 2026.
Thank you, and welcome, everyone, to today's earnings conference call for VolitionRx Limited. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance or achievements expressed or implied by these statements.
We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
